Pyridoxal 5-phosphate, PAL-P, PLP, Vitamin B6 phosphate
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||247.142 g/mol|
|Melting point||139 to 142 °C (282 to 288 °F; 412 to 415 K)|
|Flash point||296.0±32.9 °C|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P), the active form of vitamin B6, is a coenzyme in a variety of enzymatic reactions. The Enzyme commission has catalogued more than 140 PLP-dependent activities, corresponding to ~4% of all classified activities. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates.
Role as a coenzyme
PLP acts as a coenzyme in all transamination reactions, and in certain decarboxylation, deamination, and racemization reactions of amino acids. The aldehyde group of PLP forms a Schiff-base linkage (internal aldimine) with the ε-amino group of a specific lysine group of the aminotransferase enzyme. The α-amino group of the amino acid substrate displaces the ε-amino group of the active-site lysine residue in a process known as transaldimination. The resulting external aldimine can lose a proton, carbon dioxide, or an amino acid sidechain to become a quinonoid intermediate, which in turn can act as a nucleophile in several reaction pathways.
In transamination, after deprotonation the quinonoid intermediate accepts a proton at a different position to become a ketimine. The resulting ketimine is hydrolysed so that the amino group remains on the complex. In addition, PLP is used by aminotransferases (or transaminases) that act upon unusual sugars such as perosamine and desosamine. In these reactions, the PLP reacts with glutamate, which transfers its alpha-amino group to PLP to make pyridoxamine phosphate (PMP). PMP then transfers its nitrogen to the sugar, making an amino sugar.
It is also active in the condensation reaction in heme synthesis.
PLP plays a role in the conversion of levodopa into dopamine, facilitates the conversion of the excitatory neurotransmitter glutamate to the inhibitory neurotransmitter GABA, and allows SAM to be decarboxylated to form propylamine, which is a precursor to polyamines.
Non-classical examples of PLP
PLP is also found on glycogen phosphorylase in the liver, where it is used to break down glycogen in glycogenolysis when glucagon or epinephrine signals it to do so. However, this enzyme does not exploit the reactive aldehyde group, but instead utilizes the phosphate group on PLP to perform its reaction.
Although the vast majority of PLP-dependent enzymes form an internal aldimine with PLP via an active site lysine residue, some PLP-dependent enzymes do not have this lysine residue, but instead have a histidine in the active site. In such a case, the histidine cannot form the internal aldimine, and, therefore, the co-factor does not become covalently tethered to the enzyme. GDP-4-keto-6-deoxymannose-3-dehydratase (ColD) is an example of such an enzyme. Human Serine hydroxymethyltransferase 2 regulates one-carbon transfer reactions required for amino acid and nucleotide metabolism, and exists in dimeric and tetrameric forms. The dimeric SHMT2 variant is a potent inhibitor of the BRISC deubiquitylase enzyme complex, which regulates immune-based cell signaling. Recent studies show that SJMT2 tetramerization is induced by PLP. This prevents interaction with the BRISC deubiqutylase complex, potentially linking vitamin B6 levels and metabolism to inflammation. 
The pyridoxal-5′-phosphate-dependent enzymes (PLP enzymes) catalyze a myriad of biochemical reactions. Although the scope of PLP-catalyzed reactions appears to be immensely diverse, there is a simple unifying principle: in the resting state, the co-factor (PLP) is covalently bonded to the amino group of an active site lysine, forming an internal aldimine. Once the amino substrate interacts with the active site, a new Schiff base is generated, commonly referred to as the external aldimine. After this step, the mechanistic pathway for each PLP-catalyzed reaction diverges. Density functional methods have been applied to investigate the transimination reaction, and the results have shown that the reaction involves three sequential steps: (i) formation of a tetrahedral intermediate with the active site lysine and the amino substrate bonded to the PLP co-factor; (ii) non-direct proton transfer between the amino substrate and the lysine residue; and (iii) formation of the external aldimine after the dissociation of the lysine residue. The overall reaction is exothermic (−12.0 kcal/mol), the second step being rate-limiting, with 12.6 kcal/mol for the activation energy
Specificity is conferred by the fact that, of the four bonds of the alpha-carbon of the amino acid aldimine state, the bond perpendicular to the pyridine ring will be broken (Dunathan Stereoelectronic Hypothesis). Consequently, specificity is dictated by how the enzymes bind their substrates. An additional role in specificity is played by the ease of protonation of the pyridine ring nitrogen.
PLP is retained in the active site not only thanks to the lysine, but also thanks to the interaction of the phosphate group and a phosphate binding pocket and to a lesser extent thanks to base stacking of the pyridine ring with an overhanging aromatic residue, generally tyrosine (which may also partake in the acid–base catalysis). Despite the limited requirements for a PLP binding pocket, PLP enzymes belong to only five different families. These families do not correlate well with a particular type of reaction. The five families are classified as fold types followed by a Roman numeral.
- Fold Type I — aspartate aminotransferase family
- Fold Type II — tryptophan synthase family
- Fold Type III — alanine racemase family (TIM-barrel)
- Fold Type IV — D-amino acid aminotransferase family
- Fold Type V — glycogen phosphorylase family
Animals are auxotroph for this enzyme co-factor and require it or an intermediate to be supplemented, hence its classification as a vitamin B6, unlike MoCo or CoQ10 for example. PLP is synthesized from pyridoxal by the enzyme pyridoxal kinase, requiring one ATP molecule. PLP is metabolized in the liver.
Two natural pathways for PLP are currently known: one requires deoxyxylulose 5-phosphate (DXP), while the other does not, hence they are known as DXP-dependent and DXP-independent. These pathways have been studied extensively in Escherichia coli and Bacillus subtilis, respectively. Despite the disparity in the starting compounds and the different number of steps required, the two pathways possess many commonalities.
The DXP-dependent biosynthetic route requires several steps and a convergence of two branches, one producing 3-hydroxy-1-aminoacetone phosphate from erythrose 4-phosphate, while the other (single enzyme) producing deoxyxylulose 5-phosphate (DXP) from glyceraldehyde 3-phosphate (GAP) and pyruvate. The condensation product of 3-hydroxy-1-aminoacetone phosphate and deoxyxylulose 5-phosphate is pyridoxine 5'-phosphate. The condensation is catalyzed by PNP synthase, encoded by pdxJ, which creates PNP (pyridoxine 5' phosphate). The final enzyme is PNP oxidase (pdxH), which catalyzes the oxidation of the 4' hydroxyl group to an aldehyde using dioxigen, resulting in hydrogen peroxide.
The first branch is catalyzed in E. coli by enzymes encoded by epd, pdxB, serC and pdxA. These share mechanistical similarities and homology with the three enzymes in serine biosynthesis (serA (homologue of pdxB), serC, serB — however, epd is a homologue of gap), which points towards a shared evolutionary origin of the two pathways. In several species there are two homologues of the E. coli serC gene, generally one in a ser operon (serC), and the other in a pdx operon, in which case it is called pdxF.
A "serendipitous pathway" was found in an overexpression library that could suppress the auxotrophy caused by the deletion of pdxB (encoding erythronate 4 phosphate dehydrogenase) in E. coli. The serendipitous pathway was very inefficient, but was possible due to the promiscuous activity of various enzymes. It started with 3-phosphohydroxypyruvate (the product of the serA-encoded enzyme in serine biosynthesis) and did not require erythronate-4-phosphate. 3PHP was dephosphorylated, resulting in an unstable intermediate that decarboxylates spontaneously (hence the presence of the phosphate in the serine biosynthetic pathway) to glycaldehyde. Glycaldehyde was condensed with glycine and the phosphorylated product was 4-phosphohydroxythreonine (4PHT), the canonical substate for 4-PHT dehydrogenase (pdxA).
The DXP-independent PLP-biosynthetic route consists of a step catalyzed by PLP-synthase, an enzyme composed of two subunits. PdxS catalyzes the condensation of ribulose 5-phosphate, glyceraldehyde-3-phosphate, and ammonia, this latter molecules is produced by PdxT which catalyzes the production of ammonia from glutamine. PdxS is a (β/α)8 barrel (also known as a TIM-barrel) that forms a dodecamer.
The widespread utilization of PLP in central metabolism, especially in amino acid biosynthesis, and its activity in the absence of enzymes, suggests PLP may be a "prebiotic" compound—that is, one that predates the origin of organic life (not to be confused with prebiotic compounds, substances which serve as a food source for beneficial bacteria). In fact, heating NH3 and glycoaldehyde spontaneously forms a variety of pyridines, including pyridoxal. Under certain conditions, PLP is formed from cyanoacetylene, diacetylene, carbon monoxide, hydrogen, water, and a phosphoric acid.
Several inhibitors of PLP enzymes are known.
One type of inhibitor forms an electrophile with PLP, causing it to irreversibly react with the active site lysine. Acetylenic compounds (e.g. propargylglycine) and vinylic compounds (e.g. vinylglycine) are such inhibitors. A different type of inhibitor inactivates PLP, and such are α-methyl and amino-oxy substrate analogs (e.g. α-methylglutamate). Still other inhibitors have good leaving groups that nucleophilically attack the PLP. Such is chloroalanine, which inhibits a large number of enzymes.
Examples of inhibitors:
- Levothyroxine In rats given only 10 µg of D , L-thyroxine daily for 15 days, liver cysteine desulfhydrase activity disappears and serine and threonine dehydrase and alanine glutamate transaminase activities decrease about 40%. Either in vivo feeding of pyridoxal-5-phosphate or in vitro addition of the coenzyme to the liver preparations restores full activity to all these enzymes, and the slight in vitro inhibition in the presence of 10−5 M thyroxine is also reversed by pyridoxal-5-phosphate.
- The inactive form pyridoxine competitively inhibits the active pyridoxal-5'-phosphate. Consequently, symptoms of vitamin B6 supplementation in the pyridoxine form can mimic those of vitamin B6 deficiency; an effect which can be avoided by supplementing with P5P instead.
- AlaP (alanine phosphonate) inhibits alanine racemases, but its lack of specificity has prompted further designs of ALR inhibitors.
- Gabaculine and Vigabatrin inhibit GABA aminotransferase
- Canaline and 5-fluoromethylornithine inhibit ornithine aminotransferase
- Amino-oxy SAM inhibits ACC synthase
PLP Deficiency and Epilepsy
Inborn errors leading to PLP deficiency can result in Vitamin B6-responsive epilepsy. Two types of epilepsy related to PLP deficiency are pyridoxine dependent epilepsy and pyridoxal phosphate dependent epilepsy. Pyridoxine dependent epilepsy is mainly caused by mutations in the ALDH7A1 gene. Pyridoxal phosphate dependent epilepsy is mainly caused by mutations in the PNPO gene. These conditions are mainly seen in infants, beginning soon after birth or in some cases before birth.
- Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2011 ACD/Labs)
- Kozlov ÉI, L'vova MS (1978). "Stability of water-soluble vitamins and coenzymes. Hydrolysis of pyridoxal-5-phosphate in acidic, neutral, and weakly alkaline solutions". Pharmaceutical Chemistry Journal. 11 (11): 1543–9. doi:10.1007/BF00778244.
- Percudani R, Peracchi A (September 2003). "A genomic overview of pyridoxal-phosphate-dependent enzymes". EMBO Reports. 4 (9): 850–4. doi:10.1038/sj.embor.embor914. PMC 1326353. PMID 12949584.
- Dolphin D, Poulson R, Avramovic O (1986). "Vitamin B6: Pyridoxal Phosphate" (PDF). Coenzymes and Cofactors. 1, Part B. New York: Wiley Interscience. ISBN 978-0471097853.
- Toney MD (January 2005). "Reaction specificity in pyridoxal phosphate enzymes". Archives of Biochemistry and Biophysics. 433 (1): 279–87. doi:10.1016/j.abb.2004.09.037. PMID 15581583.
- Samuel G, Reeves P (November 2003). "Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly". Carbohydrate Research. 338 (23): 2503–19. doi:10.1016/j.carres.2003.07.009. PMID 14670712.
- Cook PD, Thoden JB, Holden HM (September 2006). "The structure of GDP-4-keto-6-deoxy-D-mannose-3-dehydratase: a unique coenzyme B6-dependent enzyme". Protein Science. 15 (9): 2093–106. doi:10.1110/ps.062328306. PMC 2242600. PMID 16943443.
- Eyers PA, Murphy JM (November 2016). "The evolving world of pseudoenzymes: proteins, prejudice and zombies". BMC Biology. 14 (1): 98. doi:10.1186/s12915-016-0322-x. PMC 5106787. PMID 27835992.
- Cerqueira NM, Fernandes PA, Ramos MJ (May 2011). "Computational Mechanistic Studies Addressed to the Transimination Reaction Present in All Pyridoxal 5'-Phosphate-Requiring Enzymes". Journal of Chemical Theory and Computation. 7 (5): 1356–68. doi:10.1021/ct1002219. PMID 26610130.
- Eliot AC, Kirsch JF (2004). "Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations". Annual Review of Biochemistry. 73: 383–415. doi:10.1146/annurev.biochem.73.011303.074021. PMID 15189147.
- Griswold WR, Toney MD (September 2011). "Role of the pyridine nitrogen in pyridoxal 5'-phosphate catalysis: activity of three classes of PLP enzymes reconstituted with deazapyridoxal 5'-phosphate". Journal of the American Chemical Society. 133 (37): 14823–30. doi:10.1021/ja2061006. PMID 21827189.
- Fitzpatrick TB, Amrhein N, Kappes B, Macheroux P, Tews I, Raschle T (October 2007). "Two independent routes of de novo vitamin B6 biosynthesis: not that different after all". The Biochemical Journal. 407 (1): 1–13. doi:10.1042/BJ20070765. PMID 17822383.
- Sakai A, Kita M, Tani Y (April 2004). "Recent progress of vitamin B6 biosynthesis". Journal of Nutritional Science and Vitaminology. 50 (2): 69–77. doi:10.3177/jnsv.50.69. PMID 15242009.
- Lam HM, Winkler ME (November 1990). "Metabolic relationships between pyridoxine (vitamin B6) and serine biosynthesis in Escherichia coli K-12". Journal of Bacteriology. 172 (11): 6518–28. doi:10.1128/jb.172.11.6518-6528.1990. PMC 526841. PMID 2121717.
- Kim J, Kershner JP, Novikov Y, Shoemaker RK, Copley SD (November 2010). "Three serendipitous pathways in E. coli can bypass a block in pyridoxal-5'-phosphate synthesis". Molecular Systems Biology. 6: 436. doi:10.1038/msb.2010.88. PMC 3010111. PMID 21119630.
- Zhu J, Burgner JW, Harms E, Belitsky BR, Smith JL (July 2005). "A new arrangement of (beta/alpha)8 barrels in the synthase subunit of PLP synthase". The Journal of Biological Chemistry. 280 (30): 27914–23. doi:10.1074/jbc.M503642200. PMID 15911615.
- Austin SM, Waddell TG (May 1999). "Prebiotic synthesis of vitamin B6-type compounds". Origins of Life and Evolution of the Biosphere. 29 (3): 287–96. Bibcode:1999OLEB...29..287A. doi:10.1023/A:1006532518221. PMID 10389266.
- Aylward N, Bofinger N (September 2006). "A plausible prebiotic synthesis of pyridoxal phosphate: vitamin B6 - a computational study". Biophysical Chemistry. 123 (2–3): 113–21. doi:10.1016/j.bpc.2006.04.014. PMID 16730878.
- "Inhibition by Thyroxine of Enzymes requiring Pyridoxal-5-Phosphate". doi:10.1038/179968a0. Cite journal requires
- "Biochemical Actions of Thyroid Hormones". doi:10.1152/physrev.19188.8.131.525. Cite journal requires
- "The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function". doi:10.1016/j.tiv.2017.07.009. Cite journal requires
- Anthony KG, Strych U, Yeung KR, Shoen CS, Perez O, Krause KL, et al. (2011). Ahmed N (ed.). "New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis". PLOS ONE. 6 (5): e20374. Bibcode:2011PLoSO...620374A. doi:10.1371/journal.pone.0020374. PMC 3102704. PMID 21637807.
- Wilson, Matthew P.; Plecko, Barbara; Mills, Philippa B.; Clayton, Peter T. (2019-03-20). "Disorders affecting vitamin B 6 metabolism". Journal of Inherited Metabolic Disease: jimd.12060. doi:10.1002/jimd.12060. ISSN 0141-8955. PMID 30671974.
- Reference, Genetics Home. "ALDH7A1 gene". Genetics Home Reference. Retrieved 2019-11-15.
- Reference, Genetics Home. "PNPO gene". Genetics Home Reference. Retrieved 2019-11-15.
- Reference, Genetics Home. "Pyridoxal 5'-phosphate-dependent epilepsy". Genetics Home Reference. Retrieved 2019-11-15.
- Gospe, Sidney M. (1993), Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A.; Wallace, Stephanie E. (eds.), "Pyridoxine-Dependent Epilepsy", GeneReviews®, University of Washington, Seattle, PMID 20301659, retrieved 2019-11-15